Zollinger‑Ellison Disease (MEN1) – A Patient‑Friendly Medical Guide

Overview

Zollinger‑Ellison disease (ZED) is a rare condition in which one or more gastrin‑producing tumors called gastrinomas develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to produce large amounts of acid, leading to severe peptic ulcer disease and related complications. When ZED occurs as part of the hereditary syndrome multiple endocrine neoplasia type 1 (MEN1), patients also have a predisposition to tumors of the parathyroid glands, pituitary gland, and other neuro‑endocrine tissues.

• Prevalence of sporadic ZED: ~1–3 cases per million people per year.¹
• MEN1 prevalence: about 1 in 30,000–40,000 individuals worldwide.²
• Approximately 20–30 % of patients with MEN1 develop gastrinomas, making ZED the most common functional neuro‑endocrine tumor in this syndrome.³

ZED can affect anyone, but because it is usually linked to MEN1, it often presents in the third to fifth decade of life. Both men and women are equally affected.

Symptoms

Symptoms result from hyperacidic stomach secretions and from the mass effect of the tumor. They may be intermittent early on and become more constant as disease progresses.

Gastro‑intestinal

• Refractory peptic ulcers: Ulcers that do not heal with standard therapy, often multiple and located beyond the duodenum (e.g., jejunum, ileum).
• Abdominal pain: Burning or gnawing pain, usually mid‑epigastric, that may improve with meals or antacids.
• Diarrhea: Occurs in 30–50 % of patients; can be watery, sometimes greasy, due to bile acid malabsorption from acid‑induced damage.
• Nausea & vomiting: May be precipitated by food intake or ulcer pain.
• Gastro‑esophageal reflux disease (GERD): Chronic heartburn from excess acid.
• GI bleeding: Hematemesis or melena from ulcer erosion.

Systemic

• Weight loss: From malabsorption and reduced intake.
• Fatigue & weakness: Secondary to anemia, malnutrition, or MEN1‑related hyperparathyroidism.
• Steatorrhea: Fatty stools when acid inactivates pancreatic enzymes.

Signs related to MEN1 (if present)

• Hypercalcemia symptoms (kidney stones, bone pain) from primary hyperparathyroidism.
• Headaches, visual field defects, or galactorrhea from pituitary adenomas.
• Skin lesions (angiomas, collagenomas) that may hint at MEN1.

Causes and Risk Factors

Genetic basis

ZED can be sporadic (≈70 %) or part of MEN1 syndrome (≈30 %).

• MEN1 mutation: Autosomal‑dominant loss‑of‑function mutations in the MEN1 gene (chromosome 11q13) that encodes the tumor suppressor protein menin.⁴ Over 1,300 distinct pathogenic variants have been identified.
• Sporadic gastrinomas: Usually arise from somatic mutations in genes such as PDX1, MEN1 (somatic), or KRAS, but the exact trigger is often unknown.

Risk factors

• Family history of MEN1 or confirmed MEN1 mutation.
• Age 30–50 years (peak incidence for MEN1‑related gastrinomas).
• Previous diagnosis of other MEN1 tumors (parathyroid, pituitary).
• Smoking and heavy alcohol use can worsen ulcer disease, though they do not cause gastrinomas.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is needed, especially in patients with refractory ulcers or known MEN1.

Biochemical testing

• Fasting serum gastrin: Levels > 1,000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when the gastric pH < 2.⁵
• Secretin stimulation test: Administration of IV secretin causes a paradoxical rise in gastrin (> 120 pg/mL) in ZED, helping differentiate from other hypergastrinemic states.
• Serum calcium & parathyroid hormone (PTH): Screen for MEN1‑related hyperparathyroidism.

Imaging studies

• Multiphasic CT or MRI of the abdomen: Detects primary gastrinoma and metastases (especially liver).
• Somatostatin receptor imaging (SRS): Octreotide (111In‑pentetreotide) scan or newer Ga‑68 DOTATATE PET/CT offers high sensitivity (≈85 %) for neuro‑endocrine tumors.
• Endoscopic ultrasound (EUS): Useful for small duodenal lesions < 1 cm.
• Selective arterial secretagogue injection (SASI) test: Occasionally used to localize occult gastrinomas.

Pathology

If surgical resection is performed, histology confirms a well‑differentiated neuro‑endocrine tumor staining positive for gastrin, chromogranin A, and synaptophysin.

Treatment Options

Management aims to control acid hypersecretion, remove the tumor when feasible, and address MEN1‑related lesions.

Medical therapy – acid control

• Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole (usually 60–120 mg daily) are first‑line; they effectively neutralize gastric acid and heal ulcers.
• Histamine‑2 receptor antagonists (H2RAs): Cimetidine or ranitidine may be added for breakthrough symptoms, though PPIs are superior.
• Secretin analogs (e.g., pasireotide): Investigational; may reduce gastrin secretion.

Surgical management

• Resection of localized gastrinoma: Enucleation, pancreaticoduodenectomy (Whipple), or distal pancreatectomy depending on tumor size/location.
• Debulking of metastatic disease: Liver resection or radiofrequency ablation for limited liver metastases.
• Exploratory surgery with intra‑operative ultrasound: Recommended in MEN1 patients because gastrinomas are often multiple and small.

Targeted/ systemic therapy for unresectable or metastatic disease

• Somatostatin analogs: Octreotide LAR or lanreotide reduce gastrin secretion and may slow tumor growth.
• Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE is FDA‑approved for gastro‑enteropancreatic neuro‑endocrine tumors and improves progression‑free survival.
• Cytotoxic chemotherapy: Streptozocin‑based regimens or temozolomide for high‑grade disease.
• mTOR inhibitor (everolimus) or tyrosine‑kinase inhibitor (sunitinib): Options for progressive, non‑functional neuro‑endocrine tumors.

Lifestyle & supportive care

• Low‑fat, low‑fiber diet while ulcer healing.
• Avoid NSAIDs, aspirin, and smoking.
• Calcium and vitamin D supplementation if hyperparathyroidism is present.
• Regular bone density monitoring.

Living with Zollinger‑Ellison Disease (MEN1)

Daily management tips

• Medication adherence: Take PPIs exactly as prescribed—usually 30 minutes before a meal.
• Meal timing: Small, frequent meals reduce acid load; avoid large, high‑protein meals that stimulate gastrin.
• Hydration: Adequate fluids help prevent dehydration from chronic diarrhea.
• Monitoring: Keep a symptom diary (pain, stool frequency, bleeding) to discuss with your gastroenterologist.
• Screening for other MEN1 tumors: Annual calcium, PTH, prolactin, IGF‑1, and pituitary MRI per endocrine society guidelines.⁶
• Genetic counseling: Family members should be offered MEN1 genetic testing.

Psychosocial aspects

Chronic disease can affect mental health. Consider support groups (e.g., MEN1 Alliance) and counseling. Many patients find relief in sharing experiences and coping strategies.

Prevention

Because gastrinomas are largely genetically driven, primary prevention is limited. However, risk can be mitigated:

• For MEN1 carriers: Early genetic testing and routine surveillance can detect tumors while they are small, allowing curative surgery.
• Modify aggravating factors: Quit smoking, limit alcohol, and avoid chronic NSAID use to reduce ulcer complications.
• Vaccinations: Stay up‑to‑date on Hepatitis B to protect the liver should metastatic disease require hepatic interventions.

Complications

If untreated or poorly controlled, ZED can lead to serious health problems:

• Perforated ulcer – abdominal emergency with risk of peritonitis.
• Severe gastrointestinal bleeding – may require endoscopic or surgical hemostasis.
• Gastric outlet obstruction from ulcer scarring.
• Malabsorption and nutritional deficiencies (iron, calcium, fat‑soluble vitamins).
• Metastatic disease – liver, lymph nodes, or rarely bone, leading to progressive symptoms.
• MEN1‑related complications: Hyperparathyroidism → kidney stones and osteoporosis; pituitary adenoma → visual loss or hormonal imbalance.

When to Seek Emergency Care

References

1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
2. National Institute of Diabetes and Digestive and Kidney Diseases. “Multiple endocrine neoplasia type 1.” 2022. https://www.niddk.nih.gov
3. J. L. Norton et al., “Gastrinomas in MEN1: prevalence and outcomes,” *Journal of Clinical Endocrinology & Metabolism*, vol. 104, no. 5, 2019.
4. World Health Organization. “MEN1 Gene Database.” 2021. https://www.who.int
5. American College of Gastroenterology. “Guidelines for Diagnosis and Management of Gastric Acid Hypersecretion Syndromes.” 2020.
6. Endocrine Society Clinical Practice Guideline. “Management of MEN1.” 2022. https://www.endocrine.org
7. Stupp, R. et al., “Peptide receptor radionuclide therapy in gastro‑enteropancreatic neuro‑endocrine tumors,” *Lancet Oncology*, 2021.